259 related articles for article (PubMed ID: 15629351)
1. Vaccine INDs: review of clinical holds.
Miller DL; Ross JJ
Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
[TBL] [Abstract][Full Text] [Related]
2. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
[TBL] [Abstract][Full Text] [Related]
3. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
Lapteva L; Pariser AR
J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
[TBL] [Abstract][Full Text] [Related]
4. Regulation of research: is it a drug trial or a supplement trial?
Chen ST
Fitoterapia; 2011 Jan; 82(1):14-6. PubMed ID: 21073930
[TBL] [Abstract][Full Text] [Related]
5. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
[TBL] [Abstract][Full Text] [Related]
6. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
7. Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Apr; 73(82):22800-16. PubMed ID: 18567164
[TBL] [Abstract][Full Text] [Related]
8. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
[TBL] [Abstract][Full Text] [Related]
9. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
10. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
11. Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule.
Fed Regist; 1997 Jun; 62(115):32479. PubMed ID: 10169828
[TBL] [Abstract][Full Text] [Related]
12. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
13. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
Senderowicz AM
Clin Cancer Res; 2010 Mar; 16(6):1719-25. PubMed ID: 20215544
[TBL] [Abstract][Full Text] [Related]
14. Disqualification of a clinical investigator--FDA. Final rule.
Fed Regist; 1997 Sep; 62(172):46875-6. PubMed ID: 10173286
[TBL] [Abstract][Full Text] [Related]
15. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
[TBL] [Abstract][Full Text] [Related]
16. Development and approval of vaccines in the United States.
Botstein P
Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
[TBL] [Abstract][Full Text] [Related]
17. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
[TBL] [Abstract][Full Text] [Related]
18. The IND application.
Ferkany JW; Williams M
Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234
[TBL] [Abstract][Full Text] [Related]
19. Establishment of vaccination clinics; user fees for investigational new drug (IND) influenza vaccine services and vaccines. Interim final rule and request for comments.
Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS)
Fed Regist; 2005 Jan; 70(15):3490-3. PubMed ID: 15669145
[TBL] [Abstract][Full Text] [Related]
20. Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration.
Feinsod M; Chambers WA
Ophthalmology; 2004 Oct; 111(10):1801-6. PubMed ID: 15465539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
